The global biologics contract research organizations market size was estimated at USD 14.88 billion in 2025 and is projected to reach USD 32.30 billion by 2033, growing at a CAGR of 10.3% from 2026 to 2033. The market growth is driven by rising demand for biologics, increasing outsourcing trends among pharmaceutical companies, growing requirements for personalized medicine, and cell & gene therapies. As biologic drug development becomes increasingly complex, pharmaceutical and biotechnology companies are relying on contract research organizations (CROs) to access specialized expertise, improve operational efficiency, and accelerate development timelines. The growing focus on innovative therapies and advanced biologic products is further supporting market expansion globally.

Biologics contract research organizations provide a wide range of research and development services that support biologic drug discovery, preclinical studies, clinical trials, regulatory compliance, data management, and commercialization activities. These organizations help sponsors manage the complexities associated with biologic products, including monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and gene therapies. Increasing investments in biotechnology research and the rising number of biologic candidates entering development pipelines continue to drive demand for CRO services across global healthcare markets.

Download a free sample copy of the Biologics Contract Research Organizations market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

• Asia Pacific biologics contract research organizations (CRO) market held the largest share of 47.1% of the global market in 2025. The region's leadership is supported by expanding pharmaceutical and biotechnology industries, increasing clinical research activities, a large patient population, and cost-effective research capabilities. Growing investments in healthcare infrastructure and supportive government initiatives aimed at strengthening life sciences research are contributing significantly to market growth. The availability of skilled research professionals and expanding clinical trial capabilities further reinforce the region's dominant position.
• The biologics contract research organizations (CRO) market in India is expected to grow significantly from 2026 to 2033. India has emerged as an important destination for clinical research and biologics development due to its strong scientific talent pool, expanding biotechnology sector, and competitive operating costs. Increasing investments in pharmaceutical innovation, growing research collaborations, and rising participation in global clinical trials are supporting the expansion of biologics CRO services across the country. Continued advancements in healthcare infrastructure are expected to further strengthen market growth.
• In 2025, the clinical segment held the largest market share of 75.6% by type. Clinical research services represent a critical stage in biologic drug development, requiring extensive evaluation of safety, efficacy, dosing, and regulatory compliance. The increasing number of biologics entering clinical development and the growing complexity of clinical trial protocols are driving demand for specialized clinical CRO services. Sponsors continue to rely on experienced organizations to manage trial execution, patient recruitment, monitoring, and data analysis activities.
• Based on product, monoclonal antibodies (mAbs) segment held the largest share in 2025. Monoclonal antibodies remain one of the most important categories within biologic therapeutics due to their widespread use in treating cancer, autoimmune disorders, infectious diseases, and other chronic conditions. The growing number of approved mAb therapies and expanding research efforts focused on developing next-generation antibody-based treatments are contributing significantly to the segment's leadership. Continued innovation in antibody engineering and targeted therapies is expected to support sustained growth within this category.
• In 2025, the clinical monitoring segment emerged as a leading service category. Clinical monitoring services are essential for ensuring study quality, regulatory compliance, patient safety, and data integrity throughout the clinical trial process. Effective monitoring helps sponsors maintain protocol adherence, identify potential risks, and ensure reliable study outcomes. As biologics trials become increasingly complex and multinational in scope, demand for comprehensive clinical monitoring services continues to grow, supporting the segment's strong market position.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The biologics CRO market is moderately fragmented, with a mix of large global CRO platforms and specialized regional providers. Some of the key players such as Lonza Group AG, WuXi Biologics, Samsung Biologics, Catalent, Inc., and Thermo Fisher Scientific are advancing the market through various strategic initiatives. These firms hold significant shares through integrated service offerings. In addition, mid-sized companies such as Parexel International and IQVIA compete through clinical trial capabilities and global site networks. Strategic collaborations and acquisitions remain key competitive approaches.

Key Biologics Contract Research Organizations Companies:

• Lonza Group AG
• WuXi Biologics / WuXi AppTec
• Samsung Biologics
• Catalent, Inc.
• Fujifilm Diosynth Biotechnologies
• AGC Biologics
• Thermo Fisher Scientific (Patheon)
• Boehringer Ingelheim (BioXcellence)
• Charles River Laboratories
• Parexel International
• IQVIA
• Medpace Holdings, Inc.
• Syngene International
• Eurofins Scientific
• KBI Biopharma

Explore Grand View Horizon to see global and regional level statistics related to the Biologics Contract Research Organizations Market

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments.
• Extended forecast timelines for long-term planning.
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments.
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making
• And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering